Publications by authors named "Thomas Beckers"

Claim this Profile
N
Novel inhibitors of epidermal growth factor receptor: (4-(Arylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)(1H-indol-2-yl)methanones and (1H-indol-2-yl)(4-(phenylamino)thieno[2,3-d]pyrimidin-6-yl)methanones.
Thomas Beckers, Andreas Sellmer, Emerich Eichhorn, Herwig Pongratz, Christoph Schächtele

Bioorg Med Chem· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive gene signatures for bevacizumab and cetuximab as well as cytotoxic agents.
Heinz-Herbert Fiebig, Vincent Vuaroqueaux, Andre Korrat, Frederic Foucault, Thomas Beckers

Int J Clin Pharmacol Ther· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Three-dimensional photonic crystal intermediate reflectors for enhanced light-trapping in tandem solar cells.
Johannes Upping, Andreas Bielawny, Ralf B Wehrspohn, Thomas Beckers, Reinhard Carius

Adv Mater· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: activation of MET as one mechanism for drug resistance.
Rebekka Krumbach, Julia Schüler, Michael Hofmann, Torsten Giesemann, Heinz-Herbert Fiebig, Thomas Beckers

Eur J Cancer· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity.
Siavosh Mahboobi, Andreas Sellmer, Matthias Winkler, Emerich Eichhorn, Herwig Pongratz, Thomas Beckers

J Med Chem· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chimeric tyrosine kinase-HDAC inhibitors as antiproliferative agents.
Andrea Uecker, Marit Sicker, Thomas Beckers, Siavosh Mahboobi, Daniel Hägerstrand

Anticancer Drugs· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design of chimeric histone deacetylase- and tyrosine kinase-inhibitors: a series of imatinib hybrides as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-Rbeta, and histone deacetylases.
Siavosh Mahboobi, Stefan Dove, Andreas Sellmer, Matthias Winkler, Emerich Eichhorn, Thomas Beckers

J Med Chem· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer.
Florian R Fritzsche, Wilko Weichert, Annika Röske, Volker Gekeler, Thomas Beckers

BMC Cancer· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trithiocarbonates as a novel class of HDAC inhibitors: SAR studies, isoenzyme selectivity, and pharmacological profiles.
Florian Dehmel, Steffen Weinbrenner, Heiko Julius, Thomas Ciossek, Thomas Maier, Thomas Beckers

J Med Chem· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo.
Wilko Weichert, Annika Röske, Silvia Niesporek, Aurelia Noske, Ann-Christin Buckendahl, Thomas Beckers

Clin Cancer Res· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis.
Wilko Weichert, Annika Röske, Volker Gekeler, Thomas Beckers, Matthias P A Ebert

Lancet Oncol· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A homogeneous cellular histone deacetylase assay suitable for compound profiling and robotic screening.
Thomas Ciossek, Heiko Julius, Heike Wieland, Thomas Maier, Thomas Beckers

Anal Biochem· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cell type-- dependent effects of Polo-like kinase 1 inhibition compared with targeted polo box interference in cancer cell lines.
Jenny Fink, Karl Sanders, Alexandra Rippl, Sylvia Finkernagel, Thomas L Beckers

Mol Cancer Ther· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group.
Thomas Beckers, Carmen Burkhardt, Heike Wieland, Petra Gimmnich, Thomas Ciossek

Int J Cancer· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trithiocarbonates: exploration of a new head group for HDAC inhibitors.
Florian Dehmel, Thomas Ciossek, Thomas Maier, Steffen Weinbrenner, Beate Schmidt, Thomas Beckers

Bioorg Med Chem Lett· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2-aroylindoles and 2-aroylbenzofurans with N-hydroxyacrylamide substructures as a novel series of rationally designed histone deacetylase inhibitors.
Siavosh Mahboobi, Andreas Sellmer, Heymo Höcher, Christian Garhammer, Herwig Pongratz, Thomas Beckers

J Med Chem· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors affecting the substrate specificity of histone deacetylases.
Daniel Riester, Christian Hildmann, Sylvia Grünewald, Thomas Beckers, Andreas Schwienhorst

Biochem Biophys Res Commun· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[4-(imidazol-1-yl)thiazol-2-yl]phenylamines. A novel class of highly potent colchicine site binding tubulin inhibitors: synthesis and cytotoxic activity on selected human cancer cell lines.
Siavosh Mahboobi, Andreas Sellmer, Heymo Höcher, Emerich Eichhorn, Thomas Bär, Thomas L Beckers

J Med Chem· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dephosphorylation of p-ERK1/2 in relation to tumor remission after HER-2 and Raf1 blocking therapy in a conditional mouse tumor model.
Carolin K Hausherr, Ilka B Schiffer, Susanne Gebhard, Andreas Banić, Berno Tanner, Thomas Beckers

Mol Carcinog· May 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Histone deacetylase inhibitors suppress the inducibility of nuclear factor-kappaB by tumor necrosis factor-alpha receptor-1 down-regulation.
Gabriele Imre, Volker Gekeler, Astrid Leja, Thomas Beckers, Markus Boehm

Cancer Res· May 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular alterations after Polo-like kinase 1 mRNA suppression versus pharmacologic inhibition in cancer cells.
Mathias Schmidt, Hans-Peter Hofmann, Karl Sanders, Georg Sczakiel, Thomas L Beckers

Mol Cancer Ther· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and cytotoxic activity of 2-acyl-1H-indole-4,7-diones on human cancer cell lines.
Siavosh Mahboobi, Andreas Sellmer, Emerich Eichhorn, Thomas Beckers, Heinz-Herbert Fiebig

Eur J Med Chem· January 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Switching off HER-2/neu in a tetracycline-controlled mouse tumor model leads to apoptosis and tumor-size-dependent remission.
Ilka B Schiffer, Susanne Gebhard, Carolin K Heimerdinger, Annette Heling, Jochem Hast, Thomas Beckers

Cancer Res· November 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2-aroylindoles, a novel class of potent, orally active small molecule tubulin inhibitors.
Thomas Beckers, Thomas Reissmann, Mathias Schmidt, Angelika M Burger, Heinz H Fiebig

Cancer Res· June 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bis(1H-2-indolyl)methanones as a novel class of inhibitors of the platelet-derived growth factor receptor kinase.
Siavosh Mahboobi, Steffen Teller, Herwig Pongratz, Harald Hufsky, Andreas Sellmer, Thomas Beckers

J Med Chem· February 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis